NCT00385996 - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

August 31, 2011

Conditions

Carcinoma, Non-small Cell Lung

Interventions

DRUG

Tarceva (Erlotinib)

Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.

Trial Locations (1)

10021

Weill Medical College of Cornell University, New York